Case managers help low-income women receive more timely breast cancer diagnosis

Mar 16, 2010

Case management appears to be associated with more appropriate follow-up and shorter time to diagnostic resolution among low-income women who receive an abnormal result on a mammogram, according to a report in the March 22 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

Rebecca Lobb, Sc.D., M.P.H., of the Centre for Research on Inner City Health, St. Michael's Hospital, Toronto, and colleagues studied 2,252 participants in the National Breast and Early Detection Program, which funds screening and diagnostic services for low-income, underinsured women. Case management was implemented into this program in 2001 to address barriers to follow-up care after abnormal , and free treatment was introduced in 2004.

Among women enrolled in the program between 1998 and 2007, the proportion experiencing a delay before diagnosis decreased from 33 percent to 23 percent after the implementation of case management, a risk reduction of 45 percent that did not differ by race or ethnicity. However, case management was not associated with changes in treatment delay. In addition, free treatment was not associated with the risk of delays in either diagnosis or treatment beyond the improvement associated with case management.

"Case management to assist women in overcoming logistic and psychosocial barriers to care may improve time to diagnosis among low-income women who receive free breast cancer screening and diagnostic services," the authors conclude. "Programs that provide services to coordinate care, in addition to free screening and diagnostic tests, may improve population health."

Explore further: Earlier unknown molecular-level mechanism may contribute to the growth rate of breast cancer

More information: Arch Intern Med. 2010;170[6]. doi:10.1001/archinternmed.2010.22

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

70-gene signature not cost-effective in breast cancer

Oct 18, 2014

(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published ...

User comments : 0